Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420138 | 1.00 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL17785810 | 0.86 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL22397460 | 0.82 | PNMT (0.38) | PNMTADRA2AADRA2BADRA2CBRD4 | |
| SCHEMBL10262493 | 0.80 | TRPM5 (0.37) | HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL7245975 | 0.79 | KDM1A (0.40) | PNMTADRA2AADRA2BADRA2CBRD4 | |
| SCHEMBL17785800 | 0.78 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL21172833 | 0.76 | SLC6A2 (0.38) | HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL7419580 | 0.76 | HTR2C (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL20870386 | 0.76 | SLC6A2 (0.38) | HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL21241465 | 0.76 | EPHX2 (0.39) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | disclosed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | disclosed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | CYP2S1, PRMT3, ARGLU1 | PNMT 1440/4885ADRA2A 1901/4885ADRA2B 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.